RBC Capital keeps «Outperform» on Brookfield and Cormedix but cuts targets
RBC Capital kept Outperform ratings on Brookfield and Cormedix while lowering price targets to $59 from $61 and $14 from $15, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, RBC Capital maintained its Outperform rating on Brookfield but reduced its price target from $61 to $59, a 3.3% cut. The new target implies 41.7% upside from the November 12 close of $41.64.
RBC Capital also kept its Outperform rating on Cormedix and trimmed its target from $15 to $14, a 6.7% decrease. That level implies 189.3% upside from the November 12 close of $4.84.
Rating data is provided by Benzinga.
why it matters
Adjustments like these usually reflect analysts refining their valuation while keeping a positive stance. For investors this is routine: a small cut to a target rarely moves the market on its own, but it can hint at shifting earnings expectations. Analyst targets are not price forecasts.
tags
instruments
sources
- RBC Capital maintains Brookfield at Outperform, lowers price target to $59 from $61 — TradingView, 13 November 2026 at 15:16 UTC
- RBC Capital maintains Cormedix at Outperform, lowers price target to $14 from $15 — TradingView, 13 November 2026 at 15:21 UTC
- RBC Capital maintains Corteva at Outperform, lowers price target to $11 from $17 — TradingView, 13 November 2026 at 15:22 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗